Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

Genflow reports biological age reductions in dog gene therapy study

Genflow Biosciences reports reductions in measured epigenetic age in dogs receiving SIRT6c gene therapy, selecting intravenous plasmid DNA as its lead veterinary delivery method while further follow-up continues...

October 14, 2026

Physitrack to publish Q3 2026 results on 20 October

Physitrack PLC will publish its Q3 2026 interim report on 20 October 2026 at 08:00 CET, followed by a webcast at 18:00 CET featuring CEO Henrik Molin and CFO Matt..

October 13, 2026

Verici Dx raises £8.75m through Placing and Retail Offer

Verici Dx has raised £8.75 million through a placing and retail offer, with AIM trading set to resume on 13 October 2026...

October 13, 2026

Verici Dx raises £8.5m and launches £250,000 retail share offer

October 9, 2026

Why scientific breakthroughs are creating new opportunities

Biotech investment is being driven by medical demand, advances in drug development and pharmaceutical demand for new treatments, but company selection remains critical because clinical and regulatory risks are high...

October 9, 2026

EDX Medical expands employee health screening with wider disease testing

EDX Medical is expanding employee health screening with tests designed to identify hundreds of diseases from one or two samples, with three major UK employers expected to start programmes later..

October 9, 2026

Genflow Biosciences secures Japanese patent and expands animal health partnerships

Genflow Biosciences has secured Japanese patent allowance for its SIRT6 gene therapy, with all 16 claims approved, and signed additional confidentiality agreements with animal health companies. Its regional grant application..

October 9, 2026

Physitrack expands into AI-powered physical therapy practice management

Physitrack is expanding into AI-powered electronic medical records and practice management, combining clinical documentation, scheduling and patient management with its existing digital rehabilitation technology...

October 9, 2026

Verici Dx raises £8m to expand Tutivia commercialisation and fund growth

Verici Dx plans to raise approximately £8 million through a placing and retail offer, with funds supporting commercial team expansion, marketing, laboratory investment and working capital as the company targets..

October 8, 2026

Verici Dx reports strong growth in Tutivia testing revenue

Verici Dx reports a 53% increase in Tutivia testing revenue for H1 2026, with 35 US transplant centres now using the kidney transplant test and further expansion expected...

October 8, 2026

Genflow Biosciences: SLAB-VET Results Put SIRT6 Partnering and Human Therapies in Focus (video)

October 8, 2026

Cizzle blood test enters US clinical use

The US launch moves Cizzle from development and validation into commercialisation, with the company now focused on increasing access to the test and building demand among healthcare providers...

October 7, 2026

Genflow Biosciences examines the role of genes in ageing

Genflow Biosciences is investigating a SIRT6 gene variant associated with longevity as part of its research into therapies targeting biological ageing...

October 5, 2026

Physitrack EMR attracts 100 clinics in five days

Physitrack has signed up more than 100 clinics representing over 500 potential users for early access to its new EMR, with founder pricing available until 1 January 2027...

October 5, 2026

Biotech Growth Trust targets small and mid-cap innovation as M&A activity builds

Biotech Growth Trust is focusing on small and mid-cap biotechnology companies, with its portfolio positioned around clinical and regulatory catalysts, global innovation and continued pharmaceutical M&A activity...

October 5, 2026

Genflow reports SIRT6 gene therapy results in aged dogs

Genflow reports reduced epigenetic age in dogs treated with its SIRT6c gene therapy, with pDNA selected as the lead delivery method for its veterinary programme...

October 5, 2026

Verici Dx reports 53% Tutivia revenue growth as US centre adoption expands

Verici Dx reported continued growth in Tutivia testing revenues in H1 2026, with revenue up 53% year on year and 35 US transplant centres now using the test, representing 23%..

October 1, 2026

Cizzle Bio advances lung cancer blood test towards clinical use

Cizzle Bio is moving its CIZ1B lung cancer blood test into commercial use in the US, with recent clinical research supporting its potential role as an additional tool alongside imaging..

September 30, 2026

Cizzle Biotechnology moves CIZ1B lung cancer test into commercialisation

Cizzle Biotechnology has moved its CIZ1B biomarker blood test into commercialisation after securing US clinical accreditation, with the company now focused on expanding access across North America and progressing opportunities..

September 30, 2026

Scottish Prostate Cancer Initiative targets 25,000 tests by year end

The initiative has tested more than 16,000 men since March and is targeting 25,000 tests by the end of 2026, with further testing events planned across Scotland...

September 29, 2026

News and Interview Alerts

Company Presentations

Cerillion Investor Presentation. Substantial Pipeline. Stronger Competitive Position

RECI presentation: High-yielding, controlled-risk lending supports near 10% dividend yield

Q&As

Avingtrans CEO Steve McQuillan on record revenue, nuclear demand and medical imaging progress

14 October 2026

Finsbury Growth & Income Trust: Nick Train on AI, Brands and UK Valuations

9 October 2026

Manx Financial CEO Douglas Grant on record £422.9m loan book and Payment Assist growth

8 October 2026

Chesnara reports early acquisition synergies as M&A pipeline remains strong (LON:CSN)

8 October 2026

CMC Markets – A catch up with Lord Peter Cruddas

8 October 2026

Hardman & Co

ICG Enterprise Trust: Investor questions answered and 1HFY’27 results

14 October 2026

Neuberger Private Equity Partners Limited 1H’26 results: Foot on the accelerator

8 October 2026

Chesnara Plc: Acquisitions show immediate benefits

2 September 2026

Arbuthnot Banking Group Plc 1H’26: accelerating franchise growth

4 August 2026

Real Estate Credit Investments maintains dividend as credit remains resilient

3 August 2026

Green News

Ferro-Alloy Resources appoints Peter Secker as CEO

26 October 2026

Ilika launches ORKA brand for deep-sea battery systems

22 October 2026

Drax Group Shares Offer Significant Valuation Upside as Data Centre Opportunity Remains Intact, Says Longspur Research

13 October 2026

Ampeak Energy Director Buys 500,000 shares in market purchase

6 October 2026

View all Sustainable sectors, Plcs and news >>

Search

Latest Interviews

Oriole Resources: 32.2Mt Wapouzé Resource Opens a Potential Multi-Decade Revenue Opportunity (video)

Hercules plc: £5m Q4 Wins Put £50m+ Civil Projects Ambition in Focus (video)

Avingtrans plc: Record £163m Revenue, 90% Order Cover and Adaptix Nears Commercial Breakthrough

Finsbury Growth & Income Trust Nick Train on Why AI Could Make UK Data Champions More Valuable (video)

Manx Financial Group PLC – Record Lending, European Expansion and a £1m Profit Opportunity (video)

Chesnara plc – £51m of Early Synergies, an Active M&A Funnel and the Next Cash Levers (video)

BrokerTalk

Valeura Energy growth outlook strengthens as Canaccord Genuity raises target price

5 October 2026

Cora Gold advances Sanankoro towards construction with FEED on track, Cavendish

23 September 2026

Drax strengthens FY26 outlook after strong summer trading and Bluefield acquisition, Longspur Research

23 September 2026

Meridian Holdings Delivers 16% Revenue Growth as Customer Registrations Reach Record Levels, Zacks Small-Cap Research

18 September 2026

Corero expands cybersecurity offering as sales strategy takes hold

18 September 2026

Funds

Real Estate Credit Investments reports 10.5% dividend yield and £5m Spanish loan commitment

28 October 2026

City Natural Resources Growth and Income PLC

City Natural Resources Growth and Income reports 76.6% annual NAV return

28 October 2026

Volta Finance generates €38m in interest income with 1.8x dividend cover

22 October 2026

Geiger Counter highlights strong uranium market fundamentals and growing nuclear demand

21 October 2026

City Natural Resources Chairman Christopher Casey outlines Tufton’s investment strategy

21 October 2026

View all Funds, Market Insights and news >>

FTSE 100 News

Informa cuts revenue growth outlook to 3%, maintains double-digit earnings growth guidance

27 October 2026

Reckitt raises full-year sales growth guidance after 3.3% Q3 core revenue growth

27 October 2026

GSK reports 62% response rate in ovarian cancer trial

26 October 2026

Computacenter raises FY 2026 profit forecast after strong Q3

26 October 2026

UK Broker Ratings

Cranswick PLC (CWK.L) Stock Analysis: Evaluating a 20.73% Upside Potential in Packaged Foods

28 October 2026

Coats Group PLC (COA.L) Stock Analysis: Strong Buy Ratings and 45% Potential Upside

28 October 2026

Bellway PLC (BWY.L): An Investor’s Insight into Growth Potential with a 21% Revenue Surge

28 October 2026

Chemring Group PLC (CHG.L) Investor Outlook: Exploring a 14.74% Potential Upside in the Aerospace & Defense Sector

28 October 2026

Close Brothers Group PLC (CBG.L): Analyst Ratings Signal a 34.63% Potential Upside

28 October 2026

Health

Genflow reports biological age reductions in dog gene therapy study

October 14, 2026

Physitrack to publish Q3 2026 results on 20 October

Physitrack PLC will publish its Q3 2026 interim report on 20 October 2026 at 08:00 CET, followed by a webcast at 18:00 CET featuring CEO Henrik Molin and CFO Matt Poulter. Investors will be able to submit questions through Zoom’s Q&A function...

October 13, 2026

Verici Dx raises £8.75m through Placing and Retail Offer

Verici Dx has raised £8.75 million through a placing and retail offer, with AIM trading set to resume on 13 October 2026...

October 13, 2026

Verici Dx raises £8.5m and launches £250,000 retail share offer

Verici Dx has conditionally raised £8.5 million through a placing at 0.20 pence per share, with strong support from existing and new institutional investors. The organ transplant diagnostics developer is also offering eligible UK retail investors the opportunity to participate in a separate WRAP retail offer of up to £250,000, with the proceeds to be used in the same way as the placing funds...

October 9, 2026

Why scientific breakthroughs are creating new opportunities

October 9, 2026

EDX Medical expands employee health screening with wider disease testing

EDX Medical is expanding employee health screening with tests designed to identify hundreds of diseases from one or two samples, with three major UK employers expected to start programmes later in 2026...

October 9, 2026

Genflow Biosciences secures Japanese patent and expands animal health partnerships

October 9, 2026

Physitrack expands into AI-powered physical therapy practice management

October 9, 2026

Verici Dx raises £8m to expand Tutivia commercialisation and fund growth

October 8, 2026

Verici Dx reports strong growth in Tutivia testing revenue

Verici Dx reports a 53% increase in Tutivia testing revenue for H1 2026, with 35 US transplant centres now using the kidney transplant test and further expansion expected...

October 8, 2026

Genflow Biosciences: SLAB-VET Results Put SIRT6 Partnering and Human Therapies in Focus (video)

Genflow Biosciences’ latest SLAB-VET-001 results are sharpening the commercial case for its SIRT6c platform. CEO Dr Eric Leire discusses the signals seen in naturally aged dogs, why pDNA is leading the veterinary programme, growing interest from animal health companies and how progress could feed into Genflow’s human sarcopenia strategy...

October 8, 2026

Cizzle blood test enters US clinical use

The US launch moves Cizzle from development and validation into commercialisation, with the company now focused on increasing access to the test and building demand among healthcare providers...

October 7, 2026

Genflow Biosciences examines the role of genes in ageing

Genflow Biosciences is investigating a SIRT6 gene variant associated with longevity as part of its research into therapies targeting biological ageing...

October 5, 2026

Physitrack EMR attracts 100 clinics in five days

Physitrack has signed up more than 100 clinics representing over 500 potential users for early access to its new EMR, with founder pricing available until 1 January 2027...

October 5, 2026

Biotech Growth Trust targets small and mid-cap innovation as M&A activity builds

October 5, 2026

Genflow reports SIRT6 gene therapy results in aged dogs

Genflow reports reduced epigenetic age in dogs treated with its SIRT6c gene therapy, with pDNA selected as the lead delivery method for its veterinary programme...

October 5, 2026

Verici Dx reports 53% Tutivia revenue growth as US centre adoption expands

Verici Dx reported continued growth in Tutivia testing revenues in H1 2026, with revenue up 53% year on year and 35 US transplant centres now using the test, representing 23% of annual US kidney transplants...

October 1, 2026

Cizzle Bio advances lung cancer blood test towards clinical use

Cizzle Bio is moving its CIZ1B lung cancer blood test into commercial use in the US, with recent clinical research supporting its potential role as an additional tool alongside imaging and other established diagnostic methods...

September 30, 2026

Cizzle Biotechnology moves CIZ1B lung cancer test into commercialisation

September 30, 2026

Scottish Prostate Cancer Initiative targets 25,000 tests by year end

The initiative has tested more than 16,000 men since March and is targeting 25,000 tests by the end of 2026, with further testing events planned across Scotland...

September 29, 2026